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Activation of E2F transcription factors is thought to drive the expression of genes essential 
for the transition of cells from G1 to S phase and for the initiation of DNA replication. 
However, this textbook view of E2Fs is increasingly under challenge. Here we discuss an 
alternative model for how E2Fs may work.The retinoblastoma (RB) tumor sup-
pressor pathway is frequently dereg-
ulated in cancer. Characterizing its 
downstream effectors could provide 
insight into the mechanisms driving 
the proliferation of cancer cells. The 
identification of E2F transcription fac-
tors as downstream effectors of the 
RB protein has ignited research efforts 
resulting in more than 3000 publica-
tions to date (according to PubMed). 
Target genes of E2Fs were initially 
implicated in the regulation of the G1 
to S phase transition of the cell cycle 
and in DNA replication. More recently, 
microarray and chromatin immunopre-
cipitation (ChIP) assays have shown 
that genes involved in differentiation, 
apoptosis, and DNA-damage signal-
ing pathways are also targets of E2F 
activity. Despite the wealth of data 
about E2Fs, there is still debate as to 
the actual role of these transcription 
factors: Do E2Fs drive the cell cycle or 
do they inhibit it, and is this action due 
to E2F-mediated transcriptional acti-
vation or repression?
Class Differences within the 
Family
So far, eight mammalian E2F family 
members have been identified. The 
expression of various E2Fs is differ-
entially regulated throughout the cell 
cycle, and some E2Fs are expressed 
in a cell type-specific manner. Five 
E2F family members have the ability to 
interact with the RB family of proteins 
(pRB, p107, and p130, also known as 
pocket proteins). These E2Fs harbor both transactivation domains and 
repression domains (see Figure 1A). 
When bound to pocket proteins, E2Fs 
mediate transcriptional repression; 
when released by pocket proteins, 
these E2Fs can act as transactivators, 
and target genes are expressed. For 
transcriptional activation, E2Fs form 
complexes with histone acetyl trans-
ferases (HATs) such as p300, CBP, 
P/CAF, and Tip60. For transcriptional 
repression, E2F forms complexes (via 
pocket proteins) with histone deacety-
lases (HDACs), chromatin-remodeling 
proteins such as BRG-1, and histone 
methyl transferases like SUV39H1.
To bind to DNA, E2Fs (1 through 
6) need to form heterodimers with a 
dimerization partner (DP-1 or DP-2) 
protein. E2Fs 1 to 5 all contain both 
activation and repression domains, 
yet E2Fs 1, 2, and 3 are frequently 
classified as E2F activators, whereas 
E2Fs 4, 5, and 6 are classified as 
repressors. Recently identified mem-
bers, E2F7 and E2F8, are atypical in 
that they can bind to DNA without hav-
ing to form dimers with DP-1 or DP-2. 
These new E2F members appear to 
be transcriptional repressors that act 
in a growth-inhibitory manner.
There are clear structural differ-
ences between the two better-charac-
terized subgroups: E2Fs 1 to 3 contain 
their own nuclear localization signals, 
whereas E2Fs 4 and 5 carry nuclear 
export signals (see Figure 1A). E2Fs 
4 and 5 are localized primarily in the 
nucleus when bound to pocket pro-
teins and function in repressor com-Cell 127, Deplexes; when “free” (that is, not bound 
to pocket proteins), they are excluded 
efficiently from the nucleus (Attwooll 
et al., 2004; Frolov and Dyson, 2004).
The view of E2Fs 1, 2, and 3 as 
activators is an oversimplification 
because these E2Fs also have the 
potential to form complexes with 
RB, allowing transcriptional repres-
sion to occur. In fact, E2F1 was origi-
nally identified because of its ability 
to associate with RB. In addition, 
unbound E2Fs 1, 2, and 3 are not 
necessarily always found in com-
plexes with HAT proteins. So, even 
though the division of E2Fs into acti-
vators and repressors has a molecu-
lar basis, we should not be too dog-
matic about this classification.
The Activation Model
What is the available data supporting 
the view that E2Fs are transactivators 
required for asynchronous cell-cycle 
progression? Researchers have gen-
erated mouse embryonic fibroblasts 
(MEFs) that lack one or more members 
of the E2F family (E2f1 to E2f6 individ-
ually, or both E2f1 and 2, or E2fs 1, 2, 
and 3, or E2f4 and 5). With the excep-
tion of the loss of E2f3, lack of any 
other E2F does not result in impair-
ment of cell proliferation (Attwooll et 
al., 2004). MEFs lacking E2f3 display 
a slow growth phenotype (Humbert 
et al., 2000), suggesting that E2F3 
is required to activate target genes 
and drive progression through the 
cell cycle. The most compelling data 
in support of this notion comes from cember 1, 2006 ©2006 Elsevier Inc. 871
the conditional ablation of E2f3 
in mice lacking E2f1 and E2f2, 
which results in MEFs that are 
unable to proliferate at all (Wu 
et al., 2001).
E2Fs can also be inactivated 
by targeting their dimerization 
partner, DP-1. One study used 
a dominant-negative mutant 
of DP-1, which retains its 
dimerization domain but lacks 
a DNA-binding domain (Wu 
et al., 1996) (see Figure 1B). 
This mutant sequesters DP-
dependent E2Fs (E2F1 to 6) so 
that they cannot bind to E2F 
sites in the DNA. This mutant 
DP-1 induces G1 cell-cycle 
arrest. Likewise, in another 
study, depletion of DP-1 using 
small hairpin RNAs induced 
cell-cycle arrest (Maehara et 
al., 2005). These data sug-
gest that E2Fs must bind to 
DNA in order to stimulate cel-
lular proliferation. Based on 
these findings, it seems that 
E2F-mediated transactivation 
is crucial for the expression of 
target genes, which drive cell-
cycle progression (see Figure 
2A). This activation model has 
become the textbook view of 
how E2Fs contribute to cell-
cycle regulation.
Repressing the Activation 
Model
These data, however, are in 
contrast to data from other 
studies where E2Fs are inac-
tivated in different ways. Such 
studies use a mutant E2F 
(called E2F-DB) that lacks a 
carboxyl terminus, resulting 
in a dominant-negative E2F 
that is neither an activator nor 
a repressor but still retains its 
DNA binding domain (see Fig-
ure 1B). This mutant binds to 
DNA, displacing both activator 
and repressor E2Fs from E2F-respon-
sive promoters. Most of these studies 
use an E2F1 mutant (Gonzalo et al., 
2005; Krek et al., 1995; Maehara et 
al., 2005; Rowland et al., 2002; Zhang 
et al., 1999), but one study uses an 
E2F2 mutant (Bargou et al., 1996). If 
the activation model is correct, E2F-
DB should inhibit the expression of 
target genes resulting in cell-cycle 
arrest. However, the exact opposite 
is observed: E2F-DB stimulates cellu-
lar proliferation, transforms cells, and 
makes them refractory to antiprolifer-
ative signaling by the p16INK4a-
pRB, TGFβ, and p19ARF-p53 
tumor-suppressor pathways. In 
addition, the expression of E2F 
target genes is not inhibited 
by E2F-DB but in most cases 
is switched on (Bargou et al., 
1996; Gonzalo et al., 2005; 
Krek et al., 1995; Maehara et 
al., 2005; Rowland et al., 2002; 
Zhang et al., 1999). Thus, these 
data support a model where 
E2F-mediated transactivation 
is not required for cell-cycle 
progression, and E2Fs regulate 
their target genes at the level of 
repression.
Activating the Repression 
Model
How can we reconcile these 
opposing conclusions? Are the 
data actually in conflict or is 
there an alternative model that 
incorporates all of these data? 
Although E2F1, 2, and 3 can 
be activators of transcription, 
they do not necessarily always 
act this way. It is equally pos-
sible that these E2Fs function 
primarily as “antirepressors”: 
that is, they could occupy E2F 
sites on promoters to prevent 
the binding of repressor E2Fs 
(see Figure 2A).
Recent data show that the 
proliferation defect observed 
in E2f3-deficient MEFs is 
dependent on p19ARF and that 
E2F3 is not strictly required for 
proliferation. Apparently, E2F3 
represses p19ARF, such that 
loss of E2f3 in MEFs that lack 
p19ARF no longer results in a 
proliferation defect (Aslanian et 
al., 2004). Thus, the prolifera-
tion defect exhibited by E2f3-
deficient MEFs is not a function 
of loss of target gene activation 
but rather reflects a loss of tar-
get gene repression. This cor-
responds with the earlier observation 
that the dominant-negative mutant 
E2F-DB induces expression of p19ARF. 
Together, these data demonstrate that 
p19ARF is indeed a target for repression 
by E2Fs. Illustrating the complexity of 
interactions among E2F target genes, 
Figure 1. The Family of E2F Transcription Factors
(A) Mammalian cells have at least eight different E2F transcription 
factors, some of which have multiple isoforms. E2Fs 1 to 5 can 
be either activators or repressors of transcription. If these E2Fs 
are bound by a pocket protein (pRB, p107, or p130), they form 
transcriptional repressor complexes. When not bound to pocket 
proteins, these E2Fs have the potential to act as transactivators 
by binding to histone acetyl transferases (HATs). E2Fs 1 to 3 are 
frequently referred to as the activator E2Fs. E2Fs 4 and 5 pri-
marily act as repressors as they are exported from the nucleus 
when not bound to pocket proteins. E2Fs 6 to 8 do not have 
transactivation domains and are seen strictly as repressors. E2F6 
forms repressor complexes by interacting with polycomb group 
proteins (Pc-G); E2Fs 7 and 8 act as repressors through an un-
known mechanism. E2Fs 1 to 6 bind to E2F sites on target gene 
promoters by forming dimers with DP-1 and DP-2; E2Fs 7 and 8 
bind to DNA independently of DP proteins. 
(B) Molecular tools for studying E2F functions. The E2F-DB 
dominant-negative mutant (also called dn-E2F or E2F-1 [−TA] or 
∆E2F-2) is a carboxy-terminal deletion mutant of E2F1 (or E2F2). 
This mutant lacks a transactivation domain and pocket protein-
binding domains but retains its DNA-binding domain. This mu-
tant displaces endogenous E2Fs from E2F-regulated target gene 
promoters. DN-DP1 is a deletion mutant of DP-1 that lacks its 
DNA-binding domain but retains its E2F-binding domain. This 
mutant binds to DP-dependent E2Fs and prevents them from 
binding to E2F-responsive promoters. These mutants differ be-
cause E2F-DB targets all E2Fs, whereas DN-DP1 targets only the 
DP-dependent E2Fs.872 Cell 127, December 1, 2006 ©2006 Elsevier Inc.
E2F-mediated transcriptional 
repression is also required 
downstream of p19ARF. Indeed, 
inactivation of E2Fs with E2F-
DB allows MEFs to proliferate 
even as p19ARF levels increase 
(Rowland et al., 2002). It is cur-
rently unknown which E2Fs are 
critical players downstream of 
p19ARF in signaling pathways 
that block cellular proliferation.
What about the more pro-
nounced proliferation defect 
seen in MEFs that lack E2fs 
1, 2, and 3? Are these cells 
defective in proliferation due 
to the absence of E2F-medi-
ated transactivation? Or do 
the remaining E2Fs 4 through 
8 repress promoters regulated 
by E2Fs in the absence of 
competing E2Fs 1, 2, and 3? 
We argue in favor of the latter 
model—that is, the remaining 
E2Fs that normally repress 
transcription in a regulated 
manner replace the absent 
E2Fs 1, 2, and 3 at sites in 
target gene promoters (see 
Figure 2A). The biological 
effect would be similar in both 
cases—cell-cycle arrest due 
to loss of expression of E2F 
target genes—but the under-
lying mechanism would be 
different.
Consider the opposing 
results obtained with the E2F-
DB mutant protein (which pro-
motes proliferation) and inac-
tivation of E2Fs by targeting 
DP-1 (which inhibits prolifera-
tion). One explanation could 
be that either approach may 
have nonspecific side effects. 
A more appealing explana-
tion is that DP-1 ablation pre-
vents E2Fs 1 through 6 from 
binding to DNA (binding is 
DP dependent) but does not 
prevent E2Fs 7 and 8 (atypi-
cal members that act as repressors 
and cause cell-cycle arrest) from 
binding to DNA (binding is not DP 
dependent). It seems feasible that in 
the absence of DNA binding of E2Fs 
1 to 6, the antiproliferative effects 
of the remaining two E2Fs become 
dominant. This would then resemble 
the model for proliferation deficiency 
in MEFs lacking E2fs1, 2, and 3 (see 
Figure 2A). In both cases, removal 
of a subset of E2Fs leaves the target 
gene promoter sites free for repres-
sion by the remaining E2Fs.
Flying ahead
Mammalian cells have at least 
eight different E2Fs, five of 
which can regulate both tran-
scriptional activation and 
repression. In contrast, the 
fruit fly Drosophila has only 
two E2Fs with clear-cut oppos-
ing effects: dE2F1 is strictly an 
activator, whereas dE2F2 is 
strictly a repressor. When Dro-
sophila de2f1 was deleted, E2F 
target genes were expressed 
at much lower levels resulting 
in serious proliferation defects 
(Duronio et al., 1995). The logi-
cal conclusion was that dE2F1 
is required to activate expres-
sion of its target genes. Without 
E2F-driven expression of these 
target genes, proliferation can-
not take place.
The defect imposed by loss of 
activating de2f1, however, could 
be restored by the simultane-
ous loss of repressing de2f2, 
resulting in proliferation in the 
absence of E2Fs altogether (Fro-
lov et al., 2001). These results 
indicate that in Drosophila the 
activating and repressing E2Fs 
act antagonistically and sug-
gest that in the absence of the 
activating E2F, the repressing 
E2F can exert its function in a 
dominant manner resulting in 
cell-cycle arrest. Furthermore, 
fly E2Fs apparently control the 
expression of E2F target genes 
but are not essential for prolif-
eration per se. In support of this 
view, expression of a fly dE2F1 
mutant called dE2Fi2 (which is 
the Drosophila version of mam-
malian E2F-DB) rescues the 
proliferation defect in fly larvae 
lacking de2f1 (Royzman et al., 
1999). This again suggests that 
the key function of dE2F1 is not 
related to transactivation and 
that dE2F1 may be required to 
prevent the recruitment of dE2F2 to 
E2F sites on target gene promoters.
Extrapolating these results to mam-
malian cells, this would argue in favor 
of a model where loss of activating 
E2Fs (through deletion of E2fs1, 2, and 
3 or inactivation of DP) may be com-
Figure 2. E2F Activation versus Repression
(A) Loss of E2Fs 1 to 3 prevents expression of E2F target 
genes resulting in cell-cycle arrest. Either of two mechanisms 
could be at work. (1) E2Fs 1 to 3 transactivate expression of 
E2F target genes, and when lost, E2F target gene expression 
decreases resulting in cell-cycle arrest. (2) Alternatively, E2Fs 
1 to 3 may prevent downregulation of target genes by E2Fs 
that act as repressors. These include E2Fs 4 and 5 bound 
to pocket proteins, E2F6 bound to Polycomb group proteins 
(PcG), and E2Fs 7 and 8 bound to unknown repressive pro-
teins (X). When E2Fs 1, 2, and 3 are lost, the repressor E2Fs 
are free to repress the expression of target genes resulting in 
cell-cycle arrest. This repression could be mediated by any of 
the remaining E2Fs (alone or in combination).
(B) E2F effects on the cell cycle. During asynchronous cell 
proliferation, E2F-mediated transactivation is dispensable, 
and E2Fs regulate the expression of their target genes by 
means of limited transcriptional repression. However, during 
cell-cycle exit—in response to contact inhibition or signaling 
via p19ARF/p53, TGFβ, or p16INK4a—E2F-mediated transcrip-
tional repression is required. E2F-mediated transactivation 
is only needed under specific circumstances, such as during 
cell-cycle re-entry from quiescence.Cell 127, December 1, 2006 ©2006 Elsevier Inc. 873
pensated by loss of repressing E2Fs. 
If so, complete loss of all E2Fs may 
result in deregulation of the cell cycle-
controlled expression of E2F target 
genes, yielding cells that proliferate 
proficiently but are refractory to pocket 
protein-mediated growth-inhibitory 
signals. By inference, loss of E2Fs 
should have the same effect as loss of 
pocket proteins. This is the case in the 
worm Caenorhabditis elegans where 
loss of the E2F homolog efl1 results 
in the same developmental defect as 
loss of the pRB worm homolog lin-35 
(Ceol and Horvitz, 2001). Similarly, loss 
of all three pocket proteins in mamma-
lian cells yields the same phenotype as 
expression of E2F-DB, that is, immor-
talization (Dannenberg et al., 2000; 
Rowland et al., 2002).
Notably, although fly larvae lacking 
both de2f1 and de2f2 develop rela-
tively normally, they cannot mature to 
become viable flies (Frolov et al., 2001). 
Likewise, many of the knockout mice 
lacking one or more members of the 
E2F family exhibit impaired embryonic 
development (Attwooll et al., 2004). It 
is possible that in these developmen-
tal settings, where there are periods of 
quiescence during embryonic develop-
ment, E2F-mediated transactivation is 
required (see below). However, equally, 
these developmental phenotypes may 
be a mere consequence of dysregu-
lated transcriptional repression.
Why Have a Transactivation 
Domain at All?
Why do E2Fs 1 to 5 all have transac-
tivation domains? Surely, this domain 
must have a function? And where did 
the activation model come from in the 
first place? In fact, the activation model 
was derived primarily from studies on 
cell-cycle re-entry, rather than studies 
on asynchronous proliferation of cells. 
Most of the work on endogenous E2F 
transactivation and associated HATs 
has been performed in cells that were 
synchronized by serum starvation and 
then analyzed during serum re-stimula-
tion. Recently, ChIP experiments have 
shown that during cell-cycle re-entry, 
E2F4/p130 complexes and HDACs 
are replaced on E2F-responsive pro-
moters by E2Fs 1 to 3 and HATs. The 874 Cell 127, December 1, 2006 ©2006 timing of this change corresponds 
with the increase in acetylation of his-
tones and the expression of E2F target 
genes (Frolov and Dyson, 2004). Fur-
thermore, a transactivation-deficient 
E2F mutant blocks cell-cycle re-entry 
in response to serum re-stimulation 
(Rowland et al., 2002), suggesting that 
for this function E2Fs do need their 
transactivation domain. Correspond-
ingly, upon overexpression, multiple 
E2F family members have the poten-
tial to drive immortal cells from quies-
cence into the cell cycle (DeGregori et 
al., 1997; Lukas et al., 1996), for which 
ectopic E2F requires its transactivation 
domain (Johnson et al., 1993; Lukas et 
al., 1996).
Thus, although asynchronously pro-
liferating cells may not require E2F-
mediated transactivation, cells that 
are exiting quiescence and re-entering 
the cell cycle do require the transac-
tivation domain. Cell-cycle re-entry 
appears to be a specific circumstance 
in which E2F-mediated transactivation 
is required.
Conclusions and Implications
We propose that cell-cycle progression 
is not driven by E2F transcription fac-
tors, but rather that E2Fs impose a level 
of regulation on key components of the 
cell cycle. In this way, E2Fs establish a 
link between the cell cycle and either 
cell-extrinsic or cell-intrinsic factors 
involved in cell-cycle regulation that 
may be either pro- or antimitogenic. 
Quiescent cells are driven into the cell 
cycle by mitogens in an E2F transacti-
vation-dependent manner. In contrast, 
proliferating cells can be arrested in 
an E2F repression-dependent manner 
by various signaling pathways includ-
ing those of p16INK4a/pRB, TGFβ, and 
p19ARF/p53 (see Figure 2B).
One implication of this model is that 
design of anticancer therapies that 
inactivate the total pool of E2Fs may 
be unwise as this could promote pro-
liferation of tumor cells. However, for 
cancers where cells do not proliferate 
exponentially but rather pass through 
stages of quiescence, targeting E2Fs 
would make sense as such tumor cells 
may be impaired in their potential to re-
enter the cell cycle.Elsevier Inc.REFEREnCEs
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